Brammer Bio, a cell and gene therapy contract development and manufacturing organization (CDMO), has launched its newly renovated cGMP manufacturing site in Cambridge, MA for gene therapy products. The 66,000 square-foot facility houses state-of-the-art equipment in cleanroom suites designed to accommodate a broad-range of gene therapy manufacturing process technologies.   “Our Cambridge site underwent a remarkable transformation,” said Mark Bamforth, president and chief exec...